Q-omics provides the consensus-scored SHMT1P1 profile across patient tissues and cancer cell-line models. SHMT1P1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SHMT1P1 is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, SHMT1P1 RNA expression shows 10,741 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KICH, and GBM as cancer lineages where SHMT1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SHMT1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SHMT1P1 survival associations across molecular data types. SHMT1P1 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SHMT1P1 RNA expression–survival associations across cancer types. High SHMT1P1 expression shows unfavorable associations in UVM, ACC, GBM and LUSC, but favorable associations in BLCA and UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SHMT1P1 RNA expression.
This table summarizes SHMT1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SHMT1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SHMT1P1 shows lower tumor expression in KICH, KIRP, THCA and LIHC and higher tumor expression in COAD. The KICH box plot shows higher SHMT1P1 RNA expression in normal versus tumor tissue (log2 FC = −0.072, t-test p < 0.001).
This table shows molecular features associated with SHMT1P1 in patient tissues and cancer cell lines. In patient samples, SHMT1P1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
